Molcure
MOLCURE is an AI-driven drug discovery company that accelerates the identification and optimization of therapeutic antibodies and peptides. Their platform integrates proprietary AI algorithms, including specialized machine learning models and a Large Language Model for antibodies, with extensive proprietary datasets (over 1 billion data points). They also utilize wet lab capabilities like directed evolution and next-generation sequencing. MOLCURE collaborates with pharmaceutical partners through various models, including screening, NGS, and AI analysis; AI-powered de novo discovery; AI-driven lead optimization; and consulting-based problem-solving. The company has demonstrated success in generating novel, high-affinity VHH antibodies with an 83% sub-micromolar hit rate, showcasing strong correlation with experimental data. MOLCURE was founded in 2013 and is based in Japan.
Molcure
MOLCURE is an AI-driven drug discovery company that accelerates the identification and optimization of therapeutic antibodies and peptides. Their platform integrates proprietary AI algorithms, including specialized machine learning models and a Large Language Model for antibodies, with extensive proprietary datasets (over 1 billion data points). They also utilize wet lab capabilities like directed evolution and next-generation sequencing. MOLCURE collaborates with pharmaceutical partners through various models, including screening, NGS, and AI analysis; AI-powered de novo discovery; AI-driven lead optimization; and consulting-based problem-solving. The company has demonstrated success in generating novel, high-affinity VHH antibodies with an 83% sub-micromolar hit rate, showcasing strong correlation with experimental data. MOLCURE was founded in 2013 and is based in Japan.